Erbitux flex trial

It was the more frail patients who did better, and I think that a large part of this may be because chemo and iressa were antagonistic with each other as I've alleged previously. Another approach is the one that SWOG is pursuing, which is giving a light weekly chemo. Patients start with a "loading dose" of erbitux a higher dose than the regular maintenance one, to get up to target blood levels quickly -- this is the standard way erbitux is given , then a week later the patient starts weekly low-dose taxotere and erbitux with radiation to 61 Gray full dose , and then maintenance erbitux until progression: Note that this proposes to give weekly therapy until progression to people who may be cured, so you could have people going on for more than a year.

I don't know how feasible it would really be to have people continue maintenance weekly therapy indefinitely. For anyone who is interested, details about this ongoing trial are available here.

Join The conversation. Hi Michel, Welcome to Grace though I'm very sorry you are here. Hi rednancys, Welcome to Grace. First congrats on being well 20 years out from breast cancer, chemo, and radiation.

My niece is just on the other side of the same plus Thank you Janine for your prompt reply. So glad to hear your your husband has recovered that gives me hope. I am having my mri on Thursday. Will update you. Hi Carole, Welcome to Grace. Colorectal cancer that has spread. Learn more. Head and neck cancer that has come back or spread. Starting treatment. Get help for the journey ahead. Help is available. Find help and support. Order a complimentary self-care kit Find out how.

Warning: Allergic reactions and heart attack. Treatment with ERBITUX is given in the following ways: In combination with FOLFIRI irinotecan, fluorouracil, leucovorin for patients who are being treated for this type of cancer for the first time In combination with another chemotherapy drug, irinotecan, for patients whose disease has progressed after receiving chemotherapy with irinotecan As a single agent: For patients whose disease has progressed after receiving both irinotecan and oxaliplatin For patients who are unable to tolerate chemotherapy with irinotecan ERBITUX is not approved to treat colorectal cancer in patients whose tumors have mutations in genes called RAS often called " RAS mutant" , or in patients for whom the mutational status of the RAS genes is not known.

Lung disease occurred in less than 0. Sun exposure may worsen these effects. These reactions may be life-threatening and possibly lead to death. In a study of patients with head and neck cancer, patients received either a combination of radiation and cisplatin a cancer drug , or ERBITUX in combination with radiation and cisplatin. If you have any history of heart disease or a heart condition. If you have a history of breathing problems or other lung problems.

If you are pregnant or if you plan on becoming pregnant. If you become pregnant during your treatment or within 2 months after your last dose, discuss this with your doctor. If you are breastfeeding or plan to breastfeed. Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

Secondary Outcome Measures : Progression-free Survival Time [ Time Frame: Time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, Oct , until cut-off date 18 Jul ] Duration from randomization until radiological progression based on modified World Health Organisation WHO criteria or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Try the modernized ClinicalTrials. Learn more about the modernization effort.

Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Results First Posted : October 4, Last Update Posted : June 25, Study Description. The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy.